SC
XENE icon

Stempoint Capital’s Xenon Pharmaceuticals XENE Stock Holding History

Stempoint Capital’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.59M Sell
76,075
-64,680
-46% -$3.59M 0.79% 40
2026
Q1 		$8.18M Sell
140,755
-207,850
-60% -$9.58M 1.57% 23
2025
Q4 		$15.6M Buy
348,605
+156,310
+81% +$6.56M 2.68% 12
2025
Q3 		$7.72M Buy
+192,295
New +$6.77M 1.55% 21
2025
Q2 		– Sell
-274,633
Closed -$9.21M – 80
2025
Q1 		$9.21M Sell
274,633
-101,212
-27% -$3.84M 2.94% 11
2024
Q4 		$14.7M Buy
+375,845
New +$15.5M 3.68% 6

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Stempoint Capital's XENE Position: Q2 2026 in Review

Stempoint Capital reduced its Xenon Pharmaceuticals (XENE) stake by 46% in Q2 2026, selling an estimated $3.59M and leaving 76,075 shares worth $4.59M. The position accounts for 0.79% of the portfolio, ranked #40.

Stempoint Capital first reported a position in XENE in Q4 2024 and has held it in 6 quarters since. The position peaked at $15.6M in Q4 2025. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • Stempoint Capital held 76,075 shares of Xenon Pharmaceuticals worth $4.59M as of Q2 2026.
  • Stempoint Capital sold 64,680 Xenon Pharmaceuticals shares in Q2 2026, an estimated $3.59M.
  • Xenon Pharmaceuticals made up 0.79% of Stempoint Capital's portfolio in Q2 2026, its #40 holding.
  • Stempoint Capital first reported a position in Xenon Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • Stempoint Capital's Xenon Pharmaceuticals position peaked at $15.6M in Q4 2025.
  • 315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Stempoint Capital's 13F filing for Q2 2026, filed 14 Aug 2026.